SCHEMBL184870

SCHEMBL184870

Cc1ccc(N)c(C(F)(F)F)c1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.66
FFAR4 Q5NUL3 10/20 0.57
TDP1 Q9NUW8 2/20 0.52
ALOX15 P16050 2/20 0.52
TP53 P04637 1/20 0.52
CYP3A4 P08684 1/20 0.52
THRB P10828 1/20 0.52
ALDH1A1 P00352 2/20 0.44
FFAR1 O14842 3/20 0.43
HSD17B10 Q99714 1/20 0.41
TSHR P16473 2/20 0.40
SYK P43405 1/20 0.40
GLA P06280 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
CA1 P00915 1/20 0.40
AR P10275 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20651276 0.84 SMN1; SMN2 (0.63) SMN1; SMN2FFAR4TDP1ALOX15TP53
SCHEMBL5958762 0.83 SMN1; SMN2 (0.67) SMN1; SMN2FFAR4TDP1ALOX15TP53
SCHEMBL2748456 0.82 SMN1; SMN2 (0.52) SMN1; SMN2FFAR4TDP1ALOX15TP53
SCHEMBL29441420 0.82 SMN1; SMN2 (0.52) SMN1; SMN2FFAR4TDP1ALOX15TP53
Hydrochloric Acid SCHEMBL27738830 0.80 SMN1; SMN2 (0.50) SMN1; SMN2FFAR4TDP1ALOX15TP53
SCHEMBL12352871 0.79 SMN1; SMN2 (1.00) SMN1; SMN2FFAR4TDP1ALOX15TP53
SCHEMBL5583842 0.79 AR (0.60) SMN1; SMN2FFAR4TDP1ALDH1A1POLB
SCHEMBL28669112 0.79 SMN1; SMN2 (0.57) SMN1; SMN2FFAR4TDP1ALOX15TP53
SCHEMBL10216057 0.79 SMN1; SMN2 (0.57) SMN1; SMN2FFAR4TDP1ALOX15TP53
SCHEMBL4273522 0.78 SMN1; SMN2 (0.45) SMN1; SMN2FFAR4TDP1SYKAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025243317-A1 SUBSTITUTED BICYCLIC SULFONAMIDE DERIVATIVES AS MODULATORS OF CBL-B JUBILANT BIOSYS LIMITED (IN) 2025-11-27 WO disclosed
CN-119930443-A Method for synthesizing trifluoromethyl substituted aniline by using tetradentate platinum complex as photocatalyst 九洲药业(杭州)有限公司 2025-05-06 CN disclosed
WO-2024061807-A1 ORGANIC ELECTRONIC DEVICE COMPRISING A CHARGE GENERATION LAYER NOVALED GMBH (DE) 2024-03-28 WO disclosed
EP-4013500-B1 TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS NOVARTIS AG (CH) 2023-10-25 EP disclosed
EP-3686199-B9 FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR CSTONE PHARMACEUTICALS SUZHOU CO LTD (CN) 2022-12-07 EP disclosed
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) 2022-12-06 US disclosed
WO-2022228449-A1 PREPARATION METHOD FOR POLYIMIDE RESIN AND THIN FILM THEREOF 上海瑞暨新材料科技有限公司 2022-11-03 WO disclosed
EP-3998263-A1 TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) 2022-05-18 EP disclosed
US-20220024928-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES BioVersys AG (CH) 2022-01-27 US disclosed
WO-2020163236-A1 TREATING LONG QT SYNDROME THE GENERAL HOSPITAL CORPORATION (US) 2020-08-13 WO disclosed
US-20050038296-A1 Organic electrolumescence device IDEMITSU KOSAN CO., LTD. (JP) 2005-02-17 US disclosed
US-6743948-B1 HAVING DUAL CHRYSENE RINGS LINKED BY AMINO FUNCTIONALITY HAVING FURTHER ARYL AND ALKENYL SUBSTITUTION; EFFICIENCY; HEAT RESISTANCE; DURABILITY IDEMITSU KOSAN CO., LTD. (JP) 2004-06-01 US disclosed
US-20030072966-A1 Organic electrolumescence device IDEMITSU KOSAN CO., LTD. (JP) 2003-04-17 US disclosed
WO-2002040445-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-05-23 WO disclosed
EP-1061112-A1 ORGANIC ELECTROLUMINESCENT ELEMENT IDEMITSU KOSAN COMPANY LIMITED (JP) 2000-12-20 EP disclosed
US-4745219-A Chemical intermediates and a process for their preparation MONSANTO COMPANY (US) 1988-05-17 US disclosed
US-4731450-A Process for perfluoroalkylation of aromatic derivatives RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1988-03-15 US disclosed
EP-0084320-B1 4-ALKYL-2-TRIFLUOROMETHYL ANILINES BAYER AG (DE) 1985-08-28 EP disclosed
EP-0084320-A2 4-Alkyl-2-trifluoromethyl anilines BAYER AG (DE) 1983-07-27 EP disclosed
US-4059402-A SUBLIMATION, MONOAZO DYES BAYER AKTIENGESELLSCHAFT (DT) 1977-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030072966-A1 Organic electrolumescence device ABCC1, CCND1, JUND SMN1; SMN2 2346/4885FFAR4 3535/4885TDP1 1805/4885
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof TFPI, TFPI2, F11 SMN1; SMN2 3397/4885FFAR4 1085/4885TDP1 1661/4885
US-20220024928-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES OR10J3, ORC3, CBR3 SMN1; SMN2 2417/4885FFAR4 2997/4885TDP1 4273/4885
US-20050038296-A1 Organic electrolumescence device CHRM1, SCO2, CHRM4 SMN1; SMN2 2658/4885FFAR4 3758/4885TDP1 2609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.